FGL1 Antikörper (Middle Region)

Produktnummer ABIN7879517

Dieser Kaninchen Polyklonal Antikörper detektiert spezifisch FGL1 in WB und IHC. Es zeigt Reaktivität gegenüber Proben von Human, Maus und Ratte.

Kurzübersicht für FGL1 Antikörper (Middle Region) (ABIN7879517)

Target: FGL1 (Fibrinogen-Like 1 (FGL1))

Reaktivität: Human, Maus, Ratte

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser FGL1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (IHC)

Produktdetails anti-FGL1 Antikörper

Bindungsspezifität: Middle Region

Verwendungszweck: FGL1 Antibody / Fibrinogen-like protein 1

Aufreinigung: Immunogen affinity purified

Immunogen: A synthetic peptide corresponding to a sequence in the middle region of human FGL1 was used as the immunogen for the FGL1 antibody.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the FGL1 antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Adding 0.2 mL of distilled water will yield a concentration of 500 μg/mL

Buffer: Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: After reconstitution, the FGL1 antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.

Details zu FGL1

Target: FGL1 (Fibrinogen-Like 1 (FGL1))

Andere Bezeichnung: FGL1

Hintergrund: FGL1 antibody detects Fibrinogen-like protein 1, a hepatocyte-derived secreted glycoprotein that plays dual roles in liver regeneration and immune regulation. FGL1 is structurally similar to fibrinogen beta and gamma chains but functions as an immune checkpoint ligand for LAG-3, contributing to T-cell inhibition and immune tolerance. The FGL1 antibody is widely used in immunology, oncology, and hepatic biology research to study immune evasion, regeneration, and tumor immunotherapy.

FGL1 is encoded by the FGL1 gene located on human chromosome 8p22. The protein is approximately 312 amino acids long and contains a fibrinogen-like domain that mediates binding to the lymphocyte-activation gene 3 (LAG-3) receptor. FGL1 is predominantly expressed in the liver but can also be produced by tumor cells and tissues under regenerative or inflammatory conditions. It is secreted into plasma, acting in both paracrine and systemic signaling.

The FGL1 antibody detects a 35 kilodalton protein by western blot and shows cytoplasmic and secretory vesicle localization under immunostaining. In normal physiology, FGL1 supports hepatocyte proliferation and tissue regeneration following liver injury by activating ERK and STAT3 pathways. In the immune system, FGL1 serves as a non-MHC ligand for LAG-3, suppressing effector T-cell activation and cytokine release, thereby promoting immune tolerance.

In cancer, FGL1 is frequently upregulated and mediates resistance to immunotherapies targeting the PD-1/PD-L1 axis. High expression correlates with poor prognosis in hepatocellular carcinoma, lung cancer, and melanoma. Neutralization of FGL1 enhances antitumor immunity, making it an emerging therapeutic target for combination checkpoint blockade. Beyond oncology, altered FGL1 levels are associated with metabolic disorders and liver fibrosis.

As a multifunctional factor bridging liver regeneration and immune suppression, FGL1 provides critical insights into tissue repair and immune escape. NSJ Bioreagents provides a validated FGL1 antibody optimized for western blot, immunohistochemistry, and ELISA, supporting research into immune regulation, liver biology, and cancer immunotherapy.

UniProt: Q08830